Shanghai RAAS Blood Products Co., Ltd. Class A

As of June 30, 2026, Shanghai RAAS Blood Products Co., Ltd. Class A carries a market capitalization of 28.61B, placing it among publicly traded companies globally. Its enterprise value stands at 30.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai RAAS Blood Products Co., Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Shanghai RAAS Blood Products Co., Ltd. Class A has 6.59B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shanghai RAAS Blood Products Co., Ltd. Class A maintains a current ratio of 4.49, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai RAAS Blood Products Co., Ltd. Class A recorded 216.16M in income tax expense.

As of the close on October 23, 2026, Shanghai RAAS Blood Products Co., Ltd. Class A's stock has declined approximately 28.91% over the past 52 weeks. The 50-day moving average sits at 4.95, while the 200-day moving average is 5.47.

As of June 30, 2026, Shanghai RAAS Blood Products Co., Ltd. Class A holds 1.56B in cash and equivalents against 3.54B in total debt, resulting in a net debt position of 1.89B. Total book value stands at 32.41B, with working capital of 8.24B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai RAAS Blood Products Co., Ltd. Class A paid dividends of 0.06 per share.

Shanghai RAAS Blood Products Co., Ltd. Class A's most recent stock split took place on September 28, 2016 with a 5:9 split ratio.